[PSA screening].
Screening for prostate cancer should help to detect malignancy at an early and potentially treatable stage. Serum psa has been used as a test for prostate cancer for over 20 years, but its practise is still very controversial worldwide. Studies can demostrate good aspects for screening with psa: the overall mortality and especially the metastases at stage of primary diagnosis can be reduced. A relevant factor is measuring the serum psa in younger men aged 40-50 for a baseline to evaluate the individual risk of prostate cancer. Furthermore, it is important not to exclude patients because of their age of measuring the psa. The individual life expectancy should help to decide about its usefulness. This aspect is especially important in the face of an increasing life expectancy and fitness level at old age. Further studies are needed to publish a recommendation for psa-screening. In Germany, the PROBASE is a current study to research this topic.